{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T18:02:27Z","timestamp":1794852147954,"version":"4.9.1"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,10,19]],"date-time":"2015-10-19T00:00:00Z","timestamp":1445212800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Psychiatry"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1186\/s12888-015-0644-1","type":"journal-article","created":{"date-parts":[[2015,10,19]],"date-time":"2015-10-19T13:42:58Z","timestamp":1445262178000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Remission of irreversible aripiprazole-induced tardive dystonia with clozapine: a case report"],"prefix":"10.1186","volume":"15","author":[{"given":"Soohyun","family":"Joe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jangho","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jongseok","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Choongman","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joonho","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,10,19]]},"reference":[{"issue":"Suppl 1","key":"644_CR1","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1055\/s-2000-7672","volume":"33","author":"M Marsalek","year":"2000","unstructured":"Marsalek M. Tardive drug-induced extrapyramidal syndromes. Pharmacopsychiatry. 2000;33 Suppl 1:14\u201333.","journal-title":"Pharmacopsychiatry"},{"issue":"4","key":"644_CR2","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1093\/oxfordjournals.schbul.a033415","volume":"25","author":"PN Harten van","year":"1999","unstructured":"van Harten PN, Kahn RS. Tardive dystonia. Schizophr Bull. 1999;25(4):741\u20138.","journal-title":"Schizophr Bull"},{"issue":"2","key":"644_CR3","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1097\/01.jcp.0000155823.59585.88","volume":"25","author":"MR Louza","year":"2005","unstructured":"Louza MR, Bassitt DP. Maintenance treatment of severe tardive dyskinesia with clozapine: 5\u00a0years\u2019 follow-up. J Clin Psychopharmacol. 2005;25(2):180\u20132.","journal-title":"J Clin Psychopharmacol"},{"issue":"3","key":"644_CR4","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1007\/s11940-005-0016-0","volume":"7","author":"F Skidmore","year":"2005","unstructured":"Skidmore F, Reich SG. Tardive Dystonia. Curr Treat Options Neurol. 2005;7(3):231\u20136.","journal-title":"Curr Treat Options Neurol"},{"issue":"3","key":"644_CR5","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/BF01245320","volume":"33","author":"HL Klawans Jr","year":"1972","unstructured":"Klawans Jr HL, Rubovits R. An experimental model of tardive dyskinesia. J Neural Transm. 1972;33(3):235\u201346.","journal-title":"J Neural Transm"},{"issue":"Suppl 9","key":"644_CR6","first-page":"21","volume":"65","author":"DV Jeste","year":"2004","unstructured":"Jeste DV. Tardive dyskinesia rates with atypical antipsychotics in older adults. J Clin Psychiatry. 2004;65 Suppl 9:21\u20134.","journal-title":"J Clin Psychiatry"},{"issue":"Suppl 9","key":"644_CR7","first-page":"16","volume":"65","author":"JM Kane","year":"2004","unstructured":"Kane JM. Tardive dyskinesia rates with atypical antipsychotics in adults: prevalence and incidence. J Clin Psychiatry. 2004;65 Suppl 9:16\u201320.","journal-title":"J Clin Psychiatry"},{"issue":"10","key":"644_CR8","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1001\/archpsyc.60.10.974","volume":"60","author":"G Grunder","year":"2003","unstructured":"Grunder G, Carlsson A, Wong DF. Mechanism of new antipsychotic medications: occupancy is not just antagonism. Arch Gen Psychiatry. 2003;60(10):974\u20137.","journal-title":"Arch Gen Psychiatry"},{"issue":"5","key":"644_CR9","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1097\/JCP.0b013e31814f3002","volume":"27","author":"JT Kantrowitz","year":"2007","unstructured":"Kantrowitz JT, Srihari VH, Tek C. Resolution of tardive dyskinesia after addition of aripiprazole to haloperidol depot. J Clin Psychopharmacol. 2007;27(5):525\u20136.","journal-title":"J Clin Psychopharmacol"},{"issue":"2","key":"644_CR10","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1097\/JCP.0b013e31819a4bd5","volume":"29","author":"C Lungu","year":"2009","unstructured":"Lungu C, Aia PG, Shih LC, Esper CD, Factor SA, Tarsy D. Tardive dyskinesia due to aripiprazole: report of 2 cases. J Clin Psychopharmacol. 2009;29(2):185\u20136.","journal-title":"J Clin Psychopharmacol"},{"issue":"2","key":"644_CR11","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1097\/JCP.0b013e318248590f","volume":"32","author":"N Matsuda","year":"2012","unstructured":"Matsuda N, Hashimoto N, Kusumi I, Ito K, Koyama T. Tardive laryngeal dystonia associated with aripiprazole monotherapy. J Clin Psychopharmacol. 2012;32(2):297\u20138.","journal-title":"J Clin Psychopharmacol"},{"issue":"6","key":"644_CR12","doi-asserted-by":"publisher","first-page":"378","DOI":"10.4088\/PCC.v08n0611c","volume":"8","author":"E Oommen","year":"2006","unstructured":"Oommen E, Chand PK, Sharma PS. Aripiprazole-induced tardive dystonia. Primary Care Companion J Clin Psychiatry. 2006;8(6):378\u20139.","journal-title":"Primary Care Companion J Clin Psychiatry"},{"issue":"3","key":"644_CR13","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1176\/jnp.2006.18.3.426a","volume":"18","author":"NR Pinninti","year":"2006","unstructured":"Pinninti NR, Mago R, Adityanjee. Tardive dystonia-associated prescription of aripiprazole. J Neuropsychiatry Clin Neurosci. 2006;18(3):426\u20137.","journal-title":"J Neuropsychiatry Clin Neurosci"},{"issue":"5","key":"644_CR14","doi-asserted-by":"publisher","first-page":"652","DOI":"10.4088\/JCP.09l05836gre","volume":"71","author":"JH Friedman","year":"2010","unstructured":"Friedman JH. Tardive dystonia due to aripiprazole use in a neuroleptic-naive patient. J Clin Psychiatry. 2010;71(5):652\u20133.","journal-title":"J Clin Psychiatry"},{"issue":"3","key":"644_CR15","doi-asserted-by":"publisher","DOI":"10.1176\/appi.neuropsych.11080193","volume":"24","author":"K Sato","year":"2012","unstructured":"Sato K, Yoshida K, Higuchi H. Probable aripiprazole-induced tardive writer\u2019s cramp. J Neuropsychiatry Clin Neurosci. 2012;24(3):e44.","journal-title":"J Neuropsychiatry Clin Neurosci"},{"issue":"5","key":"644_CR16","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1212\/WNL.0b013e31829d86b6","volume":"81","author":"R Bhidayasiri","year":"2013","unstructured":"Bhidayasiri R, Fahn S, Weiner WJ, Gronseth GS, Sullivan KL, Zesiewicz TA, et al. Evidence-based guideline: treatment of tardive syndromes: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2013;81(5):463\u20139.","journal-title":"Neurology"},{"issue":"2\u20133","key":"644_CR17","first-page":"231","volume":"28","author":"VW Larach","year":"1997","unstructured":"Larach VW, Zamboni RT, Mancini HR, Mancini RR, Gallardo RT. New strategies for old problems: tardive dyskinesia (TD). Review and report on severe TD cases treated with clozapine, with 12, 8 and 5\u00a0years of video follow-up. Schizophr Res. 1997;28(2\u20133):231\u201346.","journal-title":"Schizophr Res"},{"issue":"11","key":"644_CR18","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1177\/070674370505001110","volume":"50","author":"HC Margolese","year":"2005","unstructured":"Margolese HC, Chouinard G, Kolivakis TT, Beauclair L, Miller R, Annable L. Tardive dyskinesia in the era of typical and atypical antipsychotics. Part 2: Incidence and management strategies in patients with schizophrenia. Can J Psychiatr Rev Can Psychiatr. 2005;50(11):703\u201314.","journal-title":"Can J Psychiatr Rev Can Psychiatr"},{"issue":"12","key":"644_CR19","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1212\/WNL.32.12.1335","volume":"32","author":"RE Burke","year":"1982","unstructured":"Burke RE, Fahn S, Jankovic J, Marsden CD, Lang AE, Gollomp S, et al. Tardive dystonia: late-onset and persistent dystonia caused by antipsychotic drugs. Neurology. 1982;32(12):1335\u201346.","journal-title":"Neurology"},{"issue":"1","key":"644_CR20","first-page":"79","volume":"28","author":"R Chadda","year":"1986","unstructured":"Chadda R, Kulhara P. A trial of sodium valproate in tardive-dyskinesia. Indian J Psychiatry. 1986;28(1):79\u201382.","journal-title":"Indian J Psychiatry"},{"key":"644_CR21","first-page":"221","volume":"14","author":"DE Casey","year":"1988","unstructured":"Casey DE. Affective disorders and tardive dyskinesia. L\u2019Enc\u00e9phale. 1988;14:221\u20136.","journal-title":"L\u2019Enc\u00e9phale"},{"issue":"6","key":"644_CR22","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/j.ajp.2013.08.067","volume":"6","author":"N Hazari","year":"2013","unstructured":"Hazari N, Kate N, Grover S. Clozapine and tardive movement disorders: a review. Asian J Psychiatry. 2013;6(6):439\u201351.","journal-title":"Asian J Psychiatry"},{"issue":"Suppl 1","key":"644_CR23","doi-asserted-by":"publisher","first-page":"S113","DOI":"10.1016\/S1353-8020(13)70028-2","volume":"20","author":"CC Aquino","year":"2014","unstructured":"Aquino CC, Lang AE. Tardive dyskinesia syndromes: current concepts. Parkinsonism Relat Disord. 2014;20 Suppl 1:S113\u20137.","journal-title":"Parkinsonism Relat Disord"},{"key":"644_CR24","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.pnpbp.2012.10.018","volume":"46","author":"CH Cho","year":"2013","unstructured":"Cho CH, Lee HJ. Oxidative stress and tardive dyskinesia: pharmacogenetic evidence. Prog Neuro-Psychopharmacol Biol Psychiatry. 2013;46:207\u201313.","journal-title":"Prog Neuro-Psychopharmacol Biol Psychiatry"},{"issue":"10","key":"644_CR25","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1002\/mds.25107","volume":"27","author":"JT Teo","year":"2012","unstructured":"Teo JT, Edwards MJ, Bhatia K. Tardive dyskinesia is caused by maladaptive synaptic plasticity: a hypothesis. Mov Disord: Off J Movement Disord Soc. 2012;27(10):1205\u201315.","journal-title":"Mov Disord: Off J Movement Disord Soc"},{"key":"644_CR26","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1146\/annurev-med-050911-161504","volume":"64","author":"HY Meltzer","year":"2013","unstructured":"Meltzer HY. Update on typical and atypical antipsychotic drugs. Annu Rev Med. 2013;64:393\u2013406.","journal-title":"Annu Rev Med"},{"issue":"4","key":"644_CR27","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1002\/mds.870090411","volume":"9","author":"JM Trugman","year":"1994","unstructured":"Trugman JM, Leadbetter R, Zalis ME, Burgdorf RO, Wooten GF. Treatment of severe axial tardive dystonia with clozapine: case report and hypothesis. Mov Disord: Off J Movement Disord Soc. 1994;9(4):441\u20136.","journal-title":"Mov Disord: Off J Movement Disord Soc"},{"issue":"10","key":"644_CR28","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1176\/ajp.152.10.1444","volume":"152","author":"AL Nordstr\u00f6m","year":"1995","unstructured":"Nordstr\u00f6m AL, Farde L, Nyberg S, Karlsson P, Halldin C, Sedvall G. D1, D2, and 5-HT2 receptor occupancy in relation to clozapine serum concentration: a PET study of schizophrenic patients. Am J Psychiatry. 1995;152(10):1444\u20139.","journal-title":"Am J Psychiatry"},{"issue":"1","key":"644_CR29","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/0014-2999(91)90096-9","volume":"192","author":"C Bolden","year":"1991","unstructured":"Bolden C, Cusack B, Richelson E. Clozapine is a potent and selective muscarinic antagonist at the five cloned human muscarinic acetylcholine receptors expressed in CHO-K1 cells. Eur J Pharmacol. 1991;192(1):205\u20136.","journal-title":"Eur J Pharmacol"}],"container-title":["BMC Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-015-0644-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12888-015-0644-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-015-0644-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,23]],"date-time":"2017-06-23T21:34:48Z","timestamp":1498253688000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmcpsychiatry.biomedcentral.com\/articles\/10.1186\/s12888-015-0644-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10,19]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["644"],"URL":"https:\/\/doi.org\/10.1186\/s12888-015-0644-1","relation":{},"ISSN":["1471-244X"],"issn-type":[{"value":"1471-244X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,10,19]]},"article-number":"253"}}